Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)

The purpose of this study is to learn if the investigational drug depemokimab is safe and effective compared to mepolizumab for adults with EGPA that returns (relapses) or has not responded to standard treatment. Mepolizumab is approved by the FDA to treat EGPA. Both drugs are injected under the skin.

Participants come to the Perelman Center for about 18 study visits over 1 year and 2 months.

ClinicalTrials.gov ID: NCT05263934

Study Duration: 14 months

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss)